Cytokinetics Inc
CYTK64.180USD
+0.890+1.41%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
7.84BMarket Cap
LossP/E TTM
More Details of Cytokinetics Inc Company
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Cytokinetics Inc Info
Ticker SymbolCYTK
Company nameCytokinetics Inc
IPO dateApr 29, 2004
CEOBlum (Robert I)
Number of employees498
Security typeOrdinary Share
Fiscal year-endApr 29
Address350 Oyster Point Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16506243000
Websitehttps://cytokinetics.com/
Ticker SymbolCYTK
IPO dateApr 29, 2004
CEOBlum (Robert I)
Company Executives of Cytokinetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert I. Blum
Mr. Robert I. Blum
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.58K
-3.00%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, Chief Legal and Administrative Officer
Executive Vice President, Chief Legal and Administrative Officer
87.30K
--
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
74.95K
-2.67%
Dr. John T. Henderson, M.D.
Dr. John T. Henderson, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
69.35K
--
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.93K
+0.37%
Ms. Nancy J. Wysenski
Ms. Nancy J. Wysenski
Independent Director
Independent Director
25.36K
+0.39%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
17.91K
+48.87%
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
7.33K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
4.55K
--
Ms. Diane Weiser
Ms. Diane Weiser
Investors Relations
Investors Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert I. Blum
Mr. Robert I. Blum
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.58K
-3.00%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, Chief Legal and Administrative Officer
Executive Vice President, Chief Legal and Administrative Officer
87.30K
--
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
74.95K
-2.67%
Dr. John T. Henderson, M.D.
Dr. John T. Henderson, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
69.35K
--
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.93K
+0.37%
Ms. Nancy J. Wysenski
Ms. Nancy J. Wysenski
Independent Director
Independent Director
25.36K
+0.39%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
15.61%
BlackRock Institutional Trust Company, N.A.
11.13%
The Vanguard Group, Inc.
9.68%
Fidelity Management & Research Company LLC
7.71%
Wellington Management Company, LLP
6.06%
Other
49.82%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
15.61%
BlackRock Institutional Trust Company, N.A.
11.13%
The Vanguard Group, Inc.
9.68%
Fidelity Management & Research Company LLC
7.71%
Wellington Management Company, LLP
6.06%
Other
49.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
64.44%
Investment Advisor/Hedge Fund
29.00%
Hedge Fund
15.06%
Research Firm
5.22%
Pension Fund
1.87%
Private Equity
1.10%
Sovereign Wealth Fund
0.97%
Individual Investor
0.70%
Bank and Trust
0.58%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
793
145.87M
132.55%
+143.08K
2025Q3
805
145.72M
135.77%
+5.80M
2025Q2
770
139.91M
134.15%
-2.00M
2025Q1
775
138.52M
127.32%
-13.28M
2024Q4
762
134.92M
129.12%
-4.79M
2024Q3
753
139.74M
126.19%
+1.20M
2024Q2
746
139.12M
110.33%
+17.80M
2024Q1
717
121.51M
118.33%
-2.47M
2023Q4
646
117.46M
121.21%
+4.93M
2023Q3
573
113.41M
125.92%
+761.08K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
17.60M
14.71%
+4.18M
+31.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
13.82M
11.55%
-142.62K
-1.02%
Jun 30, 2025
The Vanguard Group, Inc.
11.96M
9.99%
+134.29K
+1.14%
Jun 30, 2025
Fidelity Management & Research Company LLC
8.34M
6.97%
+722.59K
+9.49%
Jun 30, 2025
Wellington Management Company, LLP
7.83M
6.54%
-161.06K
-2.02%
Jun 30, 2025
State Street Investment Management (US)
6.37M
5.33%
+287.75K
+4.73%
Jun 30, 2025
Deep Track Capital LP
3.65M
3.05%
+576.15K
+18.74%
Jun 30, 2025
Fidelity Institutional Asset Management
2.93M
2.45%
+228.79K
+8.47%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.99M
2.5%
+56.96K
+1.94%
Jun 30, 2025
BofA Global Research (US)
2.60M
2.17%
+22.66K
+0.88%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
3.11%
Tema Heart & Health ETF
2.03%
State Street SPDR S&P Biotech ETF
1.58%
T Rowe Price Capital Appreciation Equity ETF
1.38%
Virtus LifeSci Biotech Clinical Trials ETF
1.3%
ProShares Ultra Nasdaq Biotechnology
0.99%
Direxion Daily S&P Biotech Bull 3X Shares
0.97%
First Trust Mid Cap Growth AlphaDEX Fund
0.76%
Invesco Nasdaq Biotechnology ETF
0.74%
iShares Biotechnology ETF
0.66%
View more
ALPS Medical Breakthroughs ETF
Proportion3.11%
Tema Heart & Health ETF
Proportion2.03%
State Street SPDR S&P Biotech ETF
Proportion1.58%
T Rowe Price Capital Appreciation Equity ETF
Proportion1.38%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.3%
ProShares Ultra Nasdaq Biotechnology
Proportion0.99%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.97%
First Trust Mid Cap Growth AlphaDEX Fund
Proportion0.76%
Invesco Nasdaq Biotechnology ETF
Proportion0.74%
iShares Biotechnology ETF
Proportion0.66%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cytokinetics Inc?
The top five shareholders of Cytokinetics Inc are:
T. Rowe Price Investment Management, Inc. holds 17.60M shares, accounting for 14.71% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.82M shares, accounting for 11.55% of the total shares.
The Vanguard Group, Inc. holds 11.96M shares, accounting for 9.99% of the total shares.
Fidelity Management & Research Company LLC holds 8.34M shares, accounting for 6.97% of the total shares.
Wellington Management Company, LLP holds 7.83M shares, accounting for 6.54% of the total shares.
T. Rowe Price Investment Management, Inc. holds 17.60M shares, accounting for 14.71% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.82M shares, accounting for 11.55% of the total shares.
The Vanguard Group, Inc. holds 11.96M shares, accounting for 9.99% of the total shares.
Fidelity Management & Research Company LLC holds 8.34M shares, accounting for 6.97% of the total shares.
Wellington Management Company, LLP holds 7.83M shares, accounting for 6.54% of the total shares.
What are the top three shareholder types of Cytokinetics Inc?
The top three shareholder types of Cytokinetics Inc are:
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Cytokinetics Inc (CYTK)?
As of 2025Q4, 793 institutions hold shares of Cytokinetics Inc, with a combined market value of approximately 145.87M, accounting for 132.55% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.22%.
What is the biggest source of revenue for Cytokinetics Inc?
In --, the -- business generated the highest revenue for Cytokinetics Inc, amounting to -- and accounting for --% of total revenue.
